Clinical trials: Overweight, Obesity
Non-Alcoholic Fatty Liver Disease
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05292911
- Testing
- ALT-801
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Altimmune, Inc.
Atherosclerotic Cardiovascular Disease, Overweight
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Trial name
- MARITIME-CV (NCT07037433)
- Testing
- Maridebart Cafraglutide
- Where
- 783 sites in United States, Argentina and 34 more
- Volunteers
- 12,800 people
- Sponsor
- Amgen
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.
- Trial name
- NCT02918279
- Testing
- Liraglutide
- Where
- 33 sites in United States, Belgium and 3 more
- Volunteers
- 251 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in…
- Trial name
- NCT05134662
- Testing
- ALT-801
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Altimmune, Inc.
Obesity & Overweight
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general.
- Trial name
- NCT07728383
- Testing
- Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gila Therapeutics, Inc.
Dietary Supplement
To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO
The goal of this mechanistic, exploratory study is to compare the effectiveness of Oligomalt to Glucidex 40 after eating in adults with Type 2 Diabetes (T2D) and in otherwise healthy adults with overweight or obesity (HAO).
- Trial name
- LORIS-02 (NCT05963594)
- Testing
- Oligomalt, maltodextrin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Obesity
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine.
- Trial name
- NCT07184086
- Testing
- CagriSema (Cagrilintide B + semaglutide I), Low Energy Diet
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study of IBI362 9 mg in Chinese Adults With Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups.
- Trial name
- NCT06164873
- Testing
- IBI362
- Where
- China
- Volunteers
- 462 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
Gastric Electrical Stimulation (GES) for the Treatment of Obesity
The purpose of this feasibility study is to provide safety data on the implantable Exilis gastric electrical stimulation (GES) system, to individually adjust stimulation parameters to levels that are comfortable for implanted…
- Trial name
- GES (NCT01823705)
- Testing
- Exilis Implantable Gastric Electrical Stimulation (GES)
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 32 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects
The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.
- Trial name
- NCT00567255
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/day, Ancillary therapy
- Where
- 36 sites in United States
- Volunteers
- 1,496 people
- Sponsor
- Orexigen Therapeutics, Inc
Overweight, Obesity
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related…
- Trial name
- NCT07754474
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Hypercholesterolemia, Dyslipidaemias
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that…
- Conditions
- Hypercholesterolemia, Dyslipidaemias, Obesity
- Trial name
- NCT00388180
- Testing
- GW501516, GW590735
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing…
- Trial name
- NCT07752979
- Testing
- ABBV-295
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 360 people
- Sponsor
- AbbVie
Evaluate the Safety and Tolerability, Healthy and Overweight or Obese Participants
Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults
This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as…
- Trial name
- NCT07518589
- Testing
- CMS-D008
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Obesity
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose.
- Trial name
- NCT00563368
- Testing
- VI-0521, topiramate, phentermine
- Where
- 2 sites in United States
- Volunteers
- 756 people
- Sponsor
- VIVUS LLC
Healthy, Overweight and/or Obese Subjects
Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects
Clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjects
- Trial name
- NCT01764425
- Testing
- P7435
- Where
- 2 sites in India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Type 2 Diabetes, Obesity
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
The purpose of this study is to evaluate EndoBarrier Gastrointestinal Liner in the post marketing environment in subjects who are obese and have Type 2 Diabetes.
- Trial name
- NCT01114438
- Testing
- EndoBarrier Gastrointestinal Liner
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Morphic Medical Inc.
Obesity, Childhood
DAta-driven personaLIzation of a digitAl Health Solution to Support Family Caregivers of Children With Chronic Conditions
The goal of this feasibility study is to explore the needs of families with children with obesity and evaluate the impact of a combined intervention (children with obesity receiving pharmacological therapy in combination with the…
- Trial name
- DALIA (NCT06520787)
- Testing
- ACDP® and pharmacological treatment for obesity
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
- Trial name
- NCT06885021
- Testing
- HDM1002 200mg, oral, once daily, 52 weeks, HDM1002 400mg, oral, once daily, 52 weeks
- Volunteers
- 780 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.